Overview

A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Status:
RECRUITING
Trial end date:
2025-11-17
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.
Phase:
PHASE2
Details
Lead Sponsor:
Akeso